Bartell Drugs opens 14th CareClinic amid flurry of store openings
SEATTLE — Bartell Drugs opened another CareClinic by Kaiser Permanente to its roster on Monday. The new clinic, located at the company’s newest store in Snoqualmie ridge, will be open seven days a week.
“Patients come to our CareClinics for quality and convenient care,” Kaiser Permanente clinician and CareClinic chief Michael Erickson said. “We’ve proven that CareClinics live up to the promise of quickly diagnosing and treating common ailments. We get you in, taken care of and on your way for an affordable price.”
Visits to the CareClinic cost $75 for patients without health insurance, and the clinic can bill a patient’s health plan. Kaiser Permanente members can have the diagnosis and treatment plan from their visit included in their secure electronic health record and shared their care team to better facilitate coordinated care.
“Bartell Drugs guests have told us they want the ability to get care and treatment as well as everyday necessities in one place,” Bartell Drugs director of CareClinic operations John Lewis said “That’s why we’re so excited to continue our expansion in order to offer our services to more communities around the region.”
Bartell Drugs said it plans to open its 15th CareClinic in August at the Redmond Town Center Location. The Snoqualmie Ridge clinic is housed in the company’s newest store — its 67th — which is set for a public grand opening on Aug. 5. Its opening comes less than a week after Bartell Drugs opened store No. 66 in Seattle’s Green Lake Village complex with a grand opening on July 29.
While only the Snoqualmie Ridge location has a CareClinic, both it and the Green Lake Village location feature a full-service pharmacy and drive-up window, a growler fill-up area, digital photo processing center, and a hand-dipped ice cream fountain. They also contain a selection of locally made products, including Oberto jerky, Joe Chocolates and a host of craft beers and regional wines.
“Bartell’s ability to thrive is due to the loyalty of our customers,” CFO Rob Jensen said when the Green Lake Village store opened. “They appreciate that we emphasize friendly customer service and convenience, as well as having a large, unique product selection that stressed local, and personalized pharmacy services.”
FDA approves targeted acute myeloid leukemia treatment
SILVER SPRING, Md. — The Food and Drug Administration has approved a new, targeted treatment for patients with relapsed/refractory acute myeloid leukemia. Idhifa (enasidenib), from Celgene, was approved for use with the RealTime IDH2 Assay, used to detect specific mutations in the IDH2 gene in patients with acute myeloid leukemia.
“Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The use of Idhifa was associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.”
AML is a form of cancer that progresses rapidly, forming in bone marrow and resulting in an increased number of abnormal white blood cells in the bloodstream and bone marrow. The National Cancer Institute at the National Institutes of Health estimates that roughly 21,380 people will be diagnosed with the disease this year, and estimates that it will kill 10,590 patients in 2017.
We appreciate the FDA’s efforts to expedite the availability of IDHIFA for patients with this devastating disease weeks ahead of the PDUFA date,” said Mark Alles, Chief Executive Officer of Celgene. “This milestone further illustrates the value of Celgene’s unique distributed research model. Our partnership with Agios is an exceptional example of how Celgene and its collaborators can positively impact the lives of patients with high unmet needs.”
Diplomat among Crain’s fastest-growing southeast Michigan companies
FLINT, Mich. — Diplomat Pharmacy was among the fastest-growing southeast Michigan companies identified this year by Crain’s Detroit Business. The magazine’s annual Fast 50 list ranks companies based on three-year revenue growth.
“Being named among Crain's Fast 50 is an incredible triumph,” Diplomat CEO and chairman Phil Hagerman said. “We've made several great strides over the past few years. We grew in revenue from existing drugs, continued to win access to meaningful specialty drug approvals, and strengthened our expertise and national footprint across complex disease states through key acquisitions.”
Diplomat ranked second among the 50 companies on the list, set apart by its 191% revenue growth between 2013 and 2016. Crain’s highlighted Diplomat’s organic growth, access to newly approved specialty drugs and growth from acquisitions.
“Our growth is driven by all aspects of our business,” Diplomat president Paul Urick said. “We are excited to continue to grow and remain dedicated to Michigan and our hometown of Flint.”